Publication
Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.
Authors not recorded
PLoS One2016PMID 26821351PMC4731059stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerNeuroblastomacivic_curation1.00
- drugBinimetinibcivic_curation1.00
- drugEverolimuscivic_curation1.00
- geneNRAScivic_curation1.00
- variantNRAS Q61Kcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26821351
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRAS Q61K1 | ||||||||
| Binimetinib + EverolimusCombination | Neuroblastoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1002In-vitro study in 5 neuroblastoma cell lines (2 with NRAS Q61K mutation). The combination of mTOR and MEK Inhibitors synergistically blocked cell growth in NRAS mutant but not wild type cell lines. Si… (full text at CIViC) PMID 26821351 · Kiessling et al., 2016 · Open in CIViC | civic |